ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 833

11 Patients with Relapsing Polychondritis Presenting with Severe Airways Disease in One Centre in UK

Shirish Dubey1, Grace Pink2, Asad Ali2, Nicholas Hart3, Patrick Murphy4, Joanne Shakespeare5, Colin Gelder6, Chris Taylor2 and David D'Cruz7, 1Rheumatology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, 2Respiratory medicine, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, 3Respiratory medicine, St Thomas' Hospital, London, United Kingdom, 4Lane Fox Respiratory Unit, St Thomas' Hospital, London, United Kingdom, 5Respiratory physiology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, 6University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, 7Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Vasculitis Poster I: Non-ANCA-Associated and Related Disorders

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Relapsing polychondritis (RP) is a multi-system disease characterised by episodes of progressive inflammation and subsequent degeneration of cartilage and connective tissue throughout the body. RP can be associated with significant morbidity and increased mortality. Respiratory manifestations include large and small airway disease. Tracheobronchomalacia is one of the severe forms of respiratory involvement and can lead to sudden death due to collapse of the airways. RP is a rare condition with incidence of around 1 in a million. We present 11 patients who presented with severe airways disease, and subsequently were diagnosed as relapsing polychondritis from one centre in UK with catchment area of around 500,000.

Methods:

The index case was diagnosed at Louise Coote Unit with RP on the basis of tracheobronchomalacia, bilateral auricular chondritis, nasal chondritis, costochondritis and inflammatory arthritis.

All patients had presented to the difficult airways clinic at University Hospital Coventry and Warwickshire NHS Trust (UHCW) in Coventry with severe breathlessness, cough and monophonic wheeze or been admitted as emergency with severe ‘exacerbation of asthma’. RP was diagnosed using the McAdam criteria) and disease activity assessed using the Relapsing Polychondritis Disease Activity Index (RPDAI). Tracheobronchomalacia was usually initially suspected on clinical examination particularly the presence of fixed inspiratory or harsh monophonic inspiratory and expiratory wheeze. Diagnosis of tracheobronchomalacia was confirmed by a combination of lung function testing, inspiratory and expiratory CT and bronchoscopy.

Results: All patients had three or more of the six diagnostic clinical features described by McAdam et al. (1976). There was considerable delay from the onset of respiratory symptoms to the diagnosis of RP. Flow-volume loops demonstrated flattening of usually expiratory curves (intrathoracic). CT showed obvious dynamic major airway collapse on expiratory films in the majority. Other manifestations of autoimmunity, such as anti-phospholipid syndrome, or other autoimmune conditions were present in 5 patients.

Patients were initially treated with a combination of oral prednisolone and methotrexate or azathioprine. 3 patients were treated with IV Cyclophosphamide, although none responded. Five patients have been treated with continuous positive airway pressure(CPAP) to palliate airway collapse. Anti-TNF treatment was tried in 3 patients (Infliximab in one with good response, Etanercept in another 2 without response). One of these has now been switched to Abatacept, whilst the other is due to start Secukinumab.

Conclusion: Obstructive small or large airways disease is a common presentation for relapsing polychondritis which is contrary to previous reports.

Monophonic wheeze should encourage investigations for tracheobronchomalacia.


Disclosure: S. Dubey, None; G. Pink, None; A. Ali, None; N. Hart, None; P. Murphy, None; J. Shakespeare, None; C. Gelder, None; C. Taylor, None; D. D'Cruz, GlaxoSmithKline, 5, 8.

To cite this abstract in AMA style:

Dubey S, Pink G, Ali A, Hart N, Murphy P, Shakespeare J, Gelder C, Taylor C, D'Cruz D. 11 Patients with Relapsing Polychondritis Presenting with Severe Airways Disease in One Centre in UK [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/11-patients-with-relapsing-polychondritis-presenting-with-severe-airways-disease-in-one-centre-in-uk/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/11-patients-with-relapsing-polychondritis-presenting-with-severe-airways-disease-in-one-centre-in-uk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology